See every side of every news story
Published loading...Updated

Route 92 Medical’s Neurovascular Interventions Portfolio Approved in Australia - Endovascular Today

Summary by Endovascular Today
April 1, 2025—Route 92 Medical, Inc. announced approval from the Australian Therapeutic Goods Administration (TGA) for its neurovascular intervention portfolio, which includes its 0.088-inch super-bore reperfusion systems: the FreeClimb 88 catheter powered by Tenzing technology and the Monopoint-based HiPoint 88 super-bore catheter. The company introduced its technology at the Australian and New Zealand Society of Neuroradiology annual scientifi…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Endovascular Today broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.